NASDAQ:RIGL Rigel Pharmaceuticals (RIGL) Stock Price, News & Analysis $18.73 -0.75 (-3.85%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Rigel Pharmaceuticals Stock (NASDAQ:RIGL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Rigel Pharmaceuticals alerts:Sign Up Key Stats Today's Range$18.58▼$19.7250-Day Range$17.74▼$21.8552-Week Range$7.48▼$29.82Volume292,775 shsAverage Volume210,930 shsMarket Capitalization$334.71 millionP/E Ratio9.05Dividend YieldN/APrice Target$36.40Consensus RatingHold Company OverviewRigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.Read More… Rigel Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreRIGL MarketRank™: Rigel Pharmaceuticals scored higher than 56% of companies evaluated by MarketBeat, and ranked 477th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingRigel Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageRigel Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Rigel Pharmaceuticals' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth377.27% Earnings GrowthEarnings for Rigel Pharmaceuticals are expected to grow by 377.27% in the coming year, from $0.22 to $1.05 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rigel Pharmaceuticals is 9.05, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.90.Price to Earnings Ratio vs. SectorThe P/E ratio of Rigel Pharmaceuticals is 9.05, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.46.Price to Book Value per Share RatioRigel Pharmaceuticals has a P/B Ratio of 98.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Rigel Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.09% of the float of Rigel Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRigel Pharmaceuticals has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.Change versus previous monthShort interest in Rigel Pharmaceuticals has recently increased by 5.53%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRigel Pharmaceuticals does not currently pay a dividend.Dividend GrowthRigel Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.09% of the float of Rigel Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRigel Pharmaceuticals has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.Change versus previous monthShort interest in Rigel Pharmaceuticals has recently increased by 5.53%, indicating that investor sentiment is decreasing significantly. News and Social Media1.6 / 5News Sentiment0.96 News SentimentRigel Pharmaceuticals has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Rigel Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for RIGL on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Rigel Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.04% of the stock of Rigel Pharmaceuticals is held by insiders.Percentage Held by Institutions66.23% of the stock of Rigel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Rigel Pharmaceuticals' insider trading history. Receive RIGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rigel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RIGL Stock News HeadlinesRIGL Rigel Pharmaceuticals, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comRigel Pharmaceuticals (NASDAQ:RIGL) shareholders have earned a 99% return over the last yearJune 21, 2025 | finance.yahoo.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.June 30 at 2:00 AM | Paradigm Press (Ad)Rigel Pharmaceuticals' SWOT analysis: promising pipeline drives stock potentialJune 14, 2025 | investing.comRigel to Present at the Jefferies Global Healthcare ConferenceMay 28, 2025 | prnewswire.comRigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 CongressMay 22, 2025 | prnewswire.comUpgrade: Analysts Just Made A Captivating Increase To Their Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) ForecastsMay 11, 2025 | finance.yahoo.comRigel Pharmaceuticals, Inc. Just Recorded A 370% EPS Beat: Here's What Analysts Are Forecasting NextMay 9, 2025 | uk.finance.yahoo.comSee More Headlines RIGL Stock Analysis - Frequently Asked Questions How have RIGL shares performed this year? Rigel Pharmaceuticals' stock was trading at $16.82 at the beginning of the year. Since then, RIGL shares have increased by 11.4% and is now trading at $18.73. View the best growth stocks for 2025 here. How were Rigel Pharmaceuticals' earnings last quarter? Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) released its quarterly earnings data on Tuesday, May, 6th. The biotechnology company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.49. The biotechnology company had revenue of $53.33 million for the quarter, compared to the consensus estimate of $43.87 million. Rigel Pharmaceuticals had a net margin of 18.31% and a negative trailing twelve-month return on equity of 655.26%. Read the conference call transcript. When did Rigel Pharmaceuticals' stock split? Rigel Pharmaceuticals's stock reverse split on Thursday, June 27th 2024.The 1-10 reverse split was announced on Thursday, June 27th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 27th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Rigel Pharmaceuticals? Shares of RIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Rigel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rigel Pharmaceuticals investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Energy Transfer (ET), SPDR S&P 500 ETF Trust (SPY) and CRISPR Therapeutics (CRSP). Company Calendar Last Earnings5/06/2025Today6/30/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryBiotechnology Current SymbolNASDAQ:RIGL CIK1034842 Webwww.rigel.com Phone(650) 624-1100Fax650-624-1101Employees160Year Founded1996Price Target and Rating Average Stock Price Target$36.40 High Stock Price Target$57.00 Low Stock Price Target$23.00 Potential Upside/Downside+94.3%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$2.07 Trailing P/E Ratio9.05 Forward P/E Ratio85.14 P/E GrowthN/ANet Income$17.49 million Net Margins18.31% Pretax Margin18.77% Return on Equity-655.26% Return on Assets24.47% Debt Debt-to-Equity Ratio2.42 Current Ratio2.20 Quick Ratio2.13 Sales & Book Value Annual Sales$179.28 million Price / Sales1.87 Cash Flow$1.04 per share Price / Cash Flow18.06 Book Value$0.19 per share Price / Book98.58Miscellaneous Outstanding Shares17,870,000Free Float16,256,000Market Cap$334.71 million OptionableOptionable Beta1.29 Social Links 20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free Report This page (NASDAQ:RIGL) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredConsumer apocalypse imminent (7 ominous red flags)The #1 Gold play right now (not a miner, ETF, or bullion) Gold is up 237% since 2008... but one gold invest...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rigel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rigel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.